Controlling type I error rates in multi-arm clinical trials: A case for the false discovery rate. (2021)
Attributed to:
Developing efficient perpetual platform trials to study multiple treatments and multiple biomarkers
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.60080
Publication URI: https://www.repository.cam.ac.uk/handle/1810/312980
Type: Journal Article/Review